罗沙司他改善血液透析患者伴促红细胞生成素抗体介导的纯红细胞再生障碍性贫血
Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.
机构信息
Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
School of Medicine, South China University of Technology, Guangzhou, China.
出版信息
Blood Purif. 2022;51(2):189-192. doi: 10.1159/000513423. Epub 2021 Sep 9.
Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.
贫血是慢性肾脏病（CKD）的常见并发症。重组人红细胞生成素（rHu-EPO）广泛用于 CKD 患者。然而，在 rHu-EPO 治疗期间已经报道了抗红细胞生成素（anti-EPO）抗体，这会导致纯红细胞再生障碍（PRCA）。我们报告了一例 75 岁男性患者，他接受血液透析治疗已有 2 年。他在 rHu-EPO 治疗期间发生 PRCA。立即停止 rHu-EPO 治疗，并给予罗沙司他治疗。罗沙司他治疗 6 个月后，抗 EPO 抗体消失，血红蛋白恢复正常范围。结果表明，罗沙司他可用于治疗抗 EPO 抗体介导的 PRCA 患者，无需免疫抑制治疗。
Zotero 插件